Capricor receives $10M milestone from Nippon Shinyaku; HOPE-3 trial continues

CAPRICOR THERAPEUTICS, INC.

Milestone payment of $10.0 million received from Nippon Shinyaku under 2022 commercialization agreement.
Payment triggered by favorable interim futility analysis from Data Safety Monitoring Board for HOPE-3 trial.
DSMB recommended continuation of HOPE-3 trial as planned.

item 8.01

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-000197

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.